EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease

Xinyue Hong, Linzi Meng, Ningqi Dai, Hongxia Shi, Yutong Su, Qiongyi Hu, Yue Sun, Honglei Liu, Jianfen Meng, Jinchao Jia, Mengyan Wang, Chengde Yang und 3 weitere

Frontiers in Immunology · 31.07.2026 · 17

DOI: 10.3389/fimmu.2026.1709136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 31.07.2026. Verfasst von Xinyue Hong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Still's Disease, Adult-Onset, Macrophage Activation Syndrome. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is one of the most common complications of adult-onset Still’s disease (AOSD), and a leading cause of organ failure and mortality in these patients. Early diagnosis and management are crucial but can be challenging. Our study aims to develop a tool for predicting the risk of HLH/MAS in AOSD patients.

Methods

The study recruited AOSD patients admitted to Ruijin Hospital from May 2018 to May 2024. Clinical features and laboratory test results were collected within the first 3 days of hospitalization. Predictor variables were selected using LASSO regression, and a logistic regression model was subsequently developed to predict HLH/MAS. Model performance was assessed through calibration curves, receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and bootstrap internal validation.

Results

This retrospective cohort study included 190 patients with AOSD. Those who developed HLH/MAS had a higher incidence of fever and splenomegaly at admission. They also exhibited more significant reductions in blood cell counts, elevated inflammatory markers, liver dysfunction, and coagulopathy compared to patients without HLH/MAS. We developed the HLH/MAS Risk Score, which included five key predictors—body temperature, platelet count, D-dimer levels, systemic score, and initial glucocorticoid response—to assess the HLH/MAS risk in hospitalized AOSD patients. This model was visualized and demonstrated robust predictive performance, achieving an AUC of 0.86. Comparative analysis with other MAS-related models confirmed that the HLH/MAS Risk Score had competitive discriminative power.

Conclusions

In this study, we developed the HLH/MAS Risk Score, a predictive tool designed to assess the risk of HLH/MAS in AOSD patients during hospitalization. The model demonstrated strong predictive performance and provides a reliable, easy-to-use tool for the early identification of patients at high risk for HLH/MAS. Further external validation is needed to confirm its clinical applicability across diverse populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticStill's Disease, Adult-OnsetMacrophage Activation SyndromeHumansFemaleMaleAdultRetrospective StudiesRisk FactorsMiddle AgedBiomarkersROC CurveRisk AssessmentPrognosis

Stichwörter der Autor:innen

adult-onset Still’s diseaseclinical prediction toolhemophagocytic lymphohistiocytosismacrophage activation syndromepredictive model

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Rheumatology and Immunology, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.

Zitieren

APA

Hong, X., Meng, L., Dai, N., Shi, H., Su, Y., Hu, Q., Sun, Y., Liu, H., Meng, J., Jia, J., Wang, M., Yang, C., Wu, Y., Teng, J., & Chi, H. (2026). Development of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1709136

Vancouver

Hong X, Meng L, Dai N, Shi H, Su Y, Hu Q, et al. Development of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1709136

BibTeX
@article{Hong2026,
  author = {Hong, Xinyue and Meng, Linzi and Dai, Ningqi and Shi, Hongxia and Su, Yutong and Hu, Qiongyi and Sun, Yue and Liu, Honglei and Meng, Jianfen and Jia, Jinchao and Wang, Mengyan and Yang, Chengde and Wu, Yaping and Teng, Jialin and Chi, Huihui},
  title = {Development of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1709136}
}
Kostenlos starten →